Abstract-Microglial activation results in profound morphological, functional and gene expression changes that affect the pro-and anti-inflammatory mechanisms of these cells. Although statins have beneficial effects on inflammation, they have not been thoroughly investigated for their ability to affect microglial functions. Therefore the effects of rosuvastatin, one of the most commonly prescribed drugs in cardiovascular therapy, either alone or in combination with bacterial lipopolysaccharide (LPS), were profiled in pure microglial cultures derived from the forebrains of 18-dayold rat embryos. To reveal the effects of rosuvastatin on a number of pro-and anti-inflammatory mechanisms, we performed morphometric, functional and gene expression studies relating to cell adhesion and proliferation, phagocytosis, pro-and anti-inflammatory cytokine (IL-1b, tumor necrosis factor a (TNF-a) and IL-10, respectively) production, and the expression of various inflammation-related genes, including those related to the above morphological parameters and cellular functions. We found that microglia could be an important therapeutic target of rosuvastatin. In unchallenged (control) microglia, rosuvastatin inhibited proliferation and cell adhesion, but promoted microspike formation and elevated the expression of certain anti-inflammatory genes (Cxcl1, Ccl5, Mbl2), while phagocytosis or pro-and antiinflammatory cytokine production were unaffected. Moreover, rosuvastatin markedly inhibited microglial activation in LPS-challenged cells by affecting both their morphology and functions as it inhibited LPS-elicited phagocytosis and inhibited pro-inflammatory cytokine (IL-1b, TNF-a) production, concomitantly increasing the level of IL-10, an antiinflammatory cytokine. Finally, rosuvastatin beneficially and differentially affected the expression of a number of inflammation-related genes in LPS-challenged cells by inhibiting numerous pro-inflammatory and stimulating several anti-inflammatory genes. Since the microglia could elicit pro-inflammatory responses leading to neurodegeneration, it is important to attenuate such mechanisms and promote antiinflammatory properties, and develop prophylactic therapies. By beneficially regulating both pro-and anti-inflammatory microglial functions, rosuvastatin may be considered as a prophylactic agent in the prevention of inflammation-related neurological disorders. Ó 2015 The Authors. Published by Elsevier Ltd. on behalf of IBRO. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
INTRODUCTION
Microglia, the main immune cells in the central nervous system (CNS), are derived from the monocyte/macrophage lineage (Ginhoux et al., 2010) . They play important roles in both physiological and pathophysiological conditions such as traumatic injury, stroke, ischemia or neurodegenerative diseases (Kreutzberg, 1996) . In response to activation, the microglia transform from a resting state to an activated form, during which profound morphological and functional changes take place, such as process retraction, proliferation, phagocytosis and cytokine expression (Gehrmann et al., 1995; Kreutzberg, 1996; Hanisch, 2002; Luo and Chen, 2012) . Although such anti-inflammatory mechanisms are essential in protecting the CNS, activated microglial cells can also be harmful to neurons by eliciting neuroinflammation that could lead to neurodegeneration (Banati et al., 1993; Gehrmann et al., 1995; GonzalezScarano and Baltuch, 1999; Streit, 2002; Graeber, 2010; Gresa-Arribas et al., 2012; Ghosh et al., 2013) . In Alzheimer's disease (AD), for example, the microglia produce proinflammatory factors such as interleukin-1b (IL-1b) around the amyloid plaques, and these factors may themselves become important components of the AD pathology because of their ability to increase the expression of amyloid precursor protein (Cordle and Landreth, 2005; Ghosh et al., 2013) .
Accumulating evidence indicates that a sequence of events contributes to the development and progression of AD, including oxidative stress, inflammation, and altered cholesterol metabolism (Gamba et al., 2015) . neuroinflammation as oxidized cholesterol could act as a link connecting peripheral hypercholesterolemia to altered cholesterol metabolism in the brain (Gamba et al., 2015) . Cholesterol modulates the processing of amyloid precursor protein and the production of b-amyloid peptides (Shobab et al., 2005) , while removing cholesterol ameliorates the production these peptides in animal models (Bodovitz and Klein, 1996; Simons et al., 1998) .
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are the agents of first choice for the treatment of high cholesterol levels (Taylor et al., 2013) . Although their main effects are related to the lipid metabolism (inhibition of cholesterol synthesis, reduction of the levels of low-density lipoproteins and triglycerides, and stimulation of the expression of high-density lipoproteins), they also strongly modulate inflammatory cells around atherosclerotic plaques (Wierzbicki et al., 2003; Burg and Espenshade, 2011) . Apart from their therapeutic use in cardiovascular diseases, statins may also have beneficial effects in the CNS (Zipp et al., 2007; van der Most et al., 2009; Famer et al., 2010) as animal studies have demonstrated that statins attenuate neuroinflammation (Zelcer et al., 2007) and reduce senile plaques and inflammatory responses (Kurata et al., 2012) .
Interestingly, in spite of being an obvious target for statins, microglial cells have not been at the focus of statin research. There have only been a few studies to demonstrate that under in vitro circumstances the microglia respond to statins such as atorvastatin and simvastatin (Lindberg et al., 2005; Nakamichi et al., 2006) . In the present study, we investigated the effects of rosuvastatin, the most widely used and arguably the most effective statin (Nissen et al., 2006; Nicholls et al., 2011) , on cultured pure microglia cells derived from mixed cultures of 18-day-old embryonic (E18) rat forebrains under control (unstimulated) and bacterial lipopolysaccharide (LPS)-stimulated conditions (Nakamura et al., 1999; Lund et al., 2006; Gresa-Arribas et al., 2012) . To reveal the effects of rosuvastatin on a number of pro-and anti-inflammatory mechanisms, we performed morphometric, functional and gene expression studies relating to cell adhesion and proliferation, phagocytic capability, pro-and anti-inflammatory cytokine (IL-1b, tumor necrosis factor a (TNF-a) and IL-10, respectively) production, and the expression of various inflammationrelated genes, including those related to the above morphological parameters and cellular functions.
EXPERIMENTAL PROCEDURES Animals
All animal experiments were carried out in strict compliance with the European Council Directive (86/609/EEC) and EC regulations (O.J. of EC No. L 358/1, 18/12/1986 ) regarding the care and use of laboratory animals for experimental procedures, and followed the relevant Hungarian and local legislation requirements. The experimental protocols were approved by the Institutional Animal Welfare Committee of the University of Szeged (I-74-II/2009/MÁ B). The pregnant Sprague-Dawley rats (45 rats, 170-190 g) were kept under standard housing conditions and fed ad libitum.
Antibodies
For a thorough characterization of different microglial phenotypes developed in vitro, an antibody against ionized calcium-binding adaptor molecule 1 (Iba1), an intracellular actin-and Ca
2+
-binding protein expressed in the CNS specifically in macrophages and microglia (Ahmed et al., 2007) , was used in our immunocytochemical and Western blot analyses. The anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was used as an internal control in Western blot experiments (Wu et al., 2012) . Dilutions of primary and secondary antibodies, and also incubation times and blocking conditions for each antibody used were carefully tested for both immunocytochemistry and Western blot analysis. To detect the specificities of the secondary antisera, omission control experiments (staining without the primary antibody) were performed. In such cases, no fluorescent or Western blot signals were detected.
Cell cultures
Pure microglial cells were isolated from mixed primary cortical cell cultures of rat embryos of either sex by the method we described earlier (Szabo and Gulya, 2013) . Sibling embryos obtained from the same pregnancy were processed for culturing together; each pregnancy was considered as an independent experiment. Briefly, 10-12 fetal rats (E18) under anesthesia were decapitated and the frontal lobe of the cerebral cortex was removed, minced with scissors, incubated in 9 ml Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen, Carlsbad, USA) containing 1 g/l D-glucose, 110 mg/l Na-pyruvate, 4 mM L-glutamine, 3.7 g/l NaHCO 3 , 10,000 U/ml penicillin G, 10 mg/ml streptomycin sulfate, 25 lg/ml amphotericin B and 0.25% trypsin for 10 min at 37°C, and then centrifuged at 1000g for 10 min at room temperature (RT). The pellet was resuspended and washed twice in 5 ml DMEM containing 10% heat-inactivated fetal bovine serum (FBS; Invitrogen) and centrifuged for 10 min at 1000g at RT. The final pellet was resuspended in 2 ml DMEM/10% FBS, after which the cells were plated in the same medium on a poly-L-lysine-coated culture flask (75 cm 2 , 12 Â 10 6 cell/flask) and cultured at 37°C in a humidified air atmosphere supplemented with 5% CO 2 , in one or other of the following ways: (1) in poly-L-lysinecoated coverslips (15 Â 15 mm; 2 Â 10 5 cells/coverslip) for immunocytochemistry; (2) in poly-L-lysine-coated Petri dishes (60 mm Â 15 mm; 4 Â 10 5 cells/dish) for Western blot analyses and enzyme-linked immunosorbent assay (ELISA) studies; or (3) in a poly-L-lysine-coated culture flask (75 cm 2, 12 Â 10 6 cells/flask) for the subsequent generation of pure microglial cell cultures.
Secondary microglial cells were subcloned from mixed primary cultures (DIV7) maintained in a poly-Llysine-coated culture flask (75 cm 2 , 12 Â 10 6 cells/flask) by shaking the cultures at 100 rpm in a platform shaker for 30 min at 37°C. Cultures from the same pregnancy were kept separate. Microglia from the supernatant were collected by centrifugation at 3000g for 8 min at RT and resuspended in 2 ml DMEM/10% FBS. The cells were seeded at a density of 4 Â 10 5 cells/Petri dish for Western blots or 2 Â 10 5 cells/coverslip/Petri dish for immunocytochemistry, proliferation or phagocytosis assays, and cultured in DMEM in a humidified atmosphere supplemented with 5% CO 2 at 37°C. The medium was changed on the first day after seeding (subDIV1). Immunocytochemistry routinely performed on the pure microglial cultures four days after seeding (subDIV4) consistently detected a >99% incidence of the Iba1-immunopositive microglial cells for the Hoechst 33258 dye-labeled cell nuclei.
Cell culture treatments
On the fourth day of subcloning (subDIV4), DMEM was replaced and the expanded pure microglial cells were treated for 24 h with either LPS (20 ng/ml final conc., dissolved in DMEM; Sigma, St. Louis, MO, USA) or rosuvastatin (1 lM final conc., dissolved in sterile, distilled water; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) alone, or with a combination of LPS + rosuvastatin, and the effects were compared in a variety of morphological and functional tests. LPS treatment served as an immunochallenge. Four types of treatment regimens were used:
(1) control (unchallenged and untreated) cultures; (2) LPSchallenged cultures received 20 ng/ml LPS; (3) rosuvastatin-treated cultures were stimulated with 1 lM rosuvastatin; (4) LPS-challenged + rosuvastatin-treated cultures received both drugs in the indicated doses. Depending on the experiments, the treatments lasted for 6, 24 or 72 h at 37°C.
Cell adhesion and proliferation
To measure changes in cell adhesion and proliferation and cell viability, the ACEA Real-Time Cell Analysis (RTCA) system and 16-well E-Plates (Acea Biosciences, Inc., San Diego, CA, USA) were used. This system measured the electrical impedance of the cells expressed as cell index in real time. Briefly, 4 Â 10 5 pure microglial cells in poly-L-lysine-coated Petri dishes were plated as described above. On the fourth day of culturing, the cells were trypsinized, centrifuged as above and seeded into gelatin-coated 16-well E-Plates at a density of 6000 cells per well. Test doses of LPS and rosuvastatin, either alone or in combination, were added to the wells before plating. After equilibration at RT for 10 min, the E-plate was loaded into the RTCA machine and the cell index was measured continuously for 60 h using the cell microelectronic sensing technique with the xCELLigence real-time cell analysis system (RTCA DP; Acea Biosciences) as we published earlier (Ozsva´ri et al., 2010) . Cell indices at 24 h were analyzed for comparison with cell proliferation data. Data analysis was carried out with the system's dedicated software (RTCA Software 1.2; Acea Biosciences) and Excel (Microsoft Corp., Redmond, WA, USA). To estimate the number of surviving/ proliferating microglial cells after treatments, the cultures were washed twice with 2 ml phosphate-buffered saline (PBS) to remove cell debris, treated with 0.25% trypsin solution for 10 min at 37°C, collected and counted in a Burker cell counting chamber. The number of viable cells was presented as mean ± S.D.
Immunocytochemistry
Pure microglial cultures treated with different treatment regimens were fixed on coverslips with 4% formaldehyde for 5 min and rinsed with 0.05 M PBS for 2 Â 5 min. After permeabilization and blocking of the nonspecific sites in 0.05 M PBS solution containing 5% normal goat serum (Sigma), 1% heat-inactivated bovine serum albumin (Sigma) and 0.05% Triton X-100 for 30 min at 37°C, the cells on the coverslips were incubated overnight in a humidified chamber at 4°C with rabbit anti-Iba1 polyclonal antibody (1:500 final dilution; Wako, Japan), a microglia-specific actin-binding protein, in the above solution as we described previously (Szabo and Gulya, 2013) . The cultured cells were washed for 4 Â 10 min at RT in 0.05 M PBS, and then incubated with the Alexa Fluor 568 fluorochromeconjugated goat anti-rabbit antibody (1:1000 final dilution; Invitrogen) in the dark for 3 h at RT. The cells on the coverslip were washed for 4 Â 10 min in 0.05 M PBS at RT, and the nuclei were stained in 0.05 M PBS solution containing 1 mg/ml polyvinylpyrrolidone and 0.5 ll/ml Hoechst 33258 dye (Sigma). The coverslips were rinsed in distilled water for 5 min, air-dried and mounted on microscope slides in Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Cells were viewed on a Nikon Microphot-FXA epifluorescent microscope (Nikon Corp., Tokyo, Japan) and photographed with a Spot RT Color CCD camera (SPOT RT/ke, Diagnostic Instruments, Inc., Sterling Heights, MI, USA).
Western blot analysis
Cultured microglial cells (subDIV4) were collected through use of a rubber policeman, homogenized in 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 0.1% Nonidet P40, 0.1% cholic acid, 2 lg/ml leupeptin, 1 lg/ml pepstatin, 2 mM phenylmethylsulfonyl fluoride and 2 mM EDTA, and centrifuged at 10,000g for 10 min. The pellet was discarded and the protein concentration of the supernatant was determined (Lowry et al., 1951) . For the Western blot analyses, 5-10 lg of protein was separated on an SDS polyacrylamide gel (4-10% stacking gel/resolving gel), transferred onto Hybond-ECL nitrocellulose membrane (Amersham Biosciences, Little Chalfont, Buckinghamshire, England), blocked for 1 h in 5% nonfat dry milk in Tris-buffered saline (TBS) containing 0.1% Tween 20, and incubated overnight with either a rabbit anti-Iba1 polyclonal antibody (1:1000 final dilution; Wako) or a mouse anti-GAPDH monoclonal antibody (clone GAPDH-71.1; 1:20,000 final dilution; Sigma). After five rinses in 0.1% TBS-Tween 20, the membranes were incubated for 1 h with the peroxidase-conjugated goat anti-rabbit secondary antibody (1:2000 final dilution; Invitrogen) for Iba1 or with the peroxidase-conjugated rabbit anti-mouse secondary antibody (1:2000 final dilution; Sigma) for GAPDH Western blots, and washed five times as before. The enhanced chemiluminescence method (ECL Plus Western blotting detection reagents; Amersham Biosciences) was used to reveal immunoreactive bands according to the manufacturer's protocol.
In vitro phagocytosis
The fluid-phase phagocytotic capabilities of the control and variously treated pure microglial cell cultures were determined via the uptake of fluorescent microspheres (carboxylate-modified polystyrene beads, fluorescent yellow-green (kex $470 nm; kem $505 nm), aqueous suspension, 2.0 lm mean particle size; L4530, Sigma) as we described previously (Szabo and Gulya, 2013) . Unstimulated (control) and LPS-stimulated pure microglial cell cultures (subDIV4) with or without rosuvastatin were tested for 24 h. At the end of the treatment period, 1 ll of a 2.5% aqueous suspension of fluorescent microspheres per ml was added to the culture, which was then incubated for 60 min at 37°C. The cells were next washed five times with 2 ml of PBS to remove dish-or cell surfacebound residual fluorescent microspheres, and fixed with 4% formaldehyde in PBS. In another setup, we also determined the number of microglial cell membrane-associated but not phagocytosed beads. Such negative controls were treated as above with the exception that microglial cultures with beads were incubated for 60 min at 4°C. At this temperature, the number of beads associated with cell surface averaged less than 1 bead per 100 Iba1-labeled cells, thus the phagocytosis was not considered significant. For measurement of the phagocytotic activity, cells labeled with phagocytosed microbeads and processed for Iba1 immunocytochemistry were counted in 20 random fields in each treatment group (mean ± S.D.) under a 20Â or 40Â objective. Statistically significant differences were determined by a two-way ANOVA.
Determination of IL-1b, IL-10 and TNF-a
For ELISA assays, the supernatants were collected from each treatment and stored at À20°C. Concentrations of IL-1b, IL-10 and TNF-a were measured with rat-specific ELISA kits (eBioscience, Vienna, Austria). The sensitivity of IL-1b (Cat# BMS630), IL-10 (Cat# BMS629) and TNF-a (Cat#BMS622) assays was 4 pg/ml, 1.5 pg/ml and 11 pg/ml, respectively. As stated by the manufacturer, the overall intra-and interassay coefficients of variation were <10% in both cases for IL-1b and TNF-a, and <5% in both cases for IL-10.
RNA isolation
Total RNA from control and treated pure microglial cells was purified as described previously (Fabian et al., 2011) ; columns and wash buffer were from Bioneer (Viral RNA extraction kit; Daejon, South Korea). Briefly, cells were washed with PBS, incubated in lysis buffer (RA1; Macherey-Nagel, Du¨ren, Germany), then collected and mixed with 70% ethanol in RNase-free water (Bioneer). The mixture was transferred through columns (Bioneer) and washed with 350 ll 80% ethanol in diethyl pyrocarbonate-treated water, and then with 600 ll and 300 ll W2 wash buffer (Bioneer). Total RNA was eluted in 50 ll RNase free-water. One ll RNase inhibitor (Applied Biosystems, Foster City, CA, USA) was added to the samples. The quality and quantity of the isolated RNA were measured with NanoDrop1000 Version 3.8.1. (Thermo Scientific, Budapest, Hungary).
RNA expression
Reverse transcription from 3 lg of total RNA in 30 ll was performed with the High-Capacity cDNA Archive Kit (Applied Biosystems) according to the manufacturer's protocol. cDNA was diluted to 80 ll. The instrumentation included the Bravo automatic liquid handling system (Agilent Technologies, Inc., Santa Clara, CA, USA) for polymerase chain reaction (PCR) assay preparation and a LightCycler 1536 System (Roche Diagnostics Corp., Indianapolis, IN, USA) or a Light Cycler Nano Instrument (Roche) for cycling (Woudstra et al., 2013) . The expression of 116 inflammation-related genes, together with that of six control genes (see below), was measured with Universal Probe Library assays using intron-spanning gene-specific primers (Rat Immune Panel; Avidin Ltd., Szeged, Hungary, www.avidinbiotech.com/services/gene-expression) and the LightCycler 1536 DNA Probe Master kit (Roche). Moreover, the expression of certain phagocytosis-related genes such as the integrin-associated protein or cluster of differentiation 47 (Cd47, NM_019195_2), the engulfment or cell motility protein (Elmo1, NM_001108415.1), the scavenger receptor class B member 1 (Scarb1, NM_031541_1), the plasminogen activator inhibitor-1 (Serpine1, NM_012620_1), the signal-regulatory protein a (Sirpa, NM_013016_2) and the vesicle-associated membrane protein 7 (Vamp7, NM_053531_1) were also analyzed, by the Light Cycler Nano Instrument. For the 1536 System, each 2 ll PCR reaction contained 8 ng of cDNA, 0.4 ll Lightcycler DNA Probes Master (5Â), the corresponding primer set and UPL probe and the Setup Control. The PCR cycling protocol was as follows: enzyme activation at 95°C for 60 s, 50 cycles of denaturation at 95°C for 0 s, and annealing and extension at 60°C for 30 s. For the Nano Instrument, each 20 ll PCR reaction contained 20 ng cDNA, 10 ll Lightcycler DNA Probes Master (5Â), the corresponding primer set and UPL probe and the Setup Control. The PCR protocol was as follows: enzyme activation at 95°C for 10 min, 50 cycles of denaturation at 95°C for 15 s, and annealing and extension at 60°C for 30 s. Gene expression was normalized to the average values of clathrin, heavy chain (Cltc, NM_019299.1), glyceraldehyde-3-phosphate-dehydrogen ase (Gapdh, M17701.1), glucuronidase, beta (Gusb, NM_017015.2), hypoxanthine phosphoribosyltransferase 1 (Hprt1, NM_012583.2), phosphoglycerate kinase 1 (Pgk1, NM_053291.3), and tubulin, beta 5 class I (Tubb5, NM_173102.2) expression as endogenous controls and expressed relative to the unstimulated controls by using the 2 ÀDDCt method. A total of 122 gene-specific assays were run on four independent samples from each condition. Student's t-test and a two-way ANOVA were applied for the analysis of significance where p < 0.05 was considered significant. For hierarchical cluster analysis and visualization, the Hierarchical Clustering Explorer (v3.0) software was used (publicly available at http:// www.cs.umd.edu/hcil/multi-cluster/hce3.html). The complete linkage clustering method was applied with Euclidean distance metric.
Image analysis and statistics
Digital images were captured by a Nikon Microphot-FXA epifluorescent microscope (Nikon Corp., Tokyo, Japan), using a Spot RT Color CCD camera and the Spot RT software (Spot RT/ke Diagnostic Instruments, Sterling Heights, MI, USA). For the determination of microglial cell purity, Hoechst 33258-labeled cell nuclei that belonged to Iba1-immunopositive cells were counted on coverslip-cultured samples. For each culture, 50-100 randomly selected microscope fields were analyzed. In every case, the cultures had, on average, at least 99 Iba1-positive somata for 100 Hoechst 33258-labeled cell nuclei (>99% purity for microglial cells). Phagocytosed microspheres on 20 randomly sampled microscope fields from three coverslips for each treatment regimen were counted with the use of the computer program ImageJ (version 1.47; http://rsb.info. nih.gov/ij). For the measurement of area (lm 2 ), perimeter (lm) and transformation index (TI), Iba1-immunoreactive microglial cell images were converted into binary replicas by using thresholding procedures implemented by ImageJ and Adobe Photoshop CS5.1 software (Adobe Systems, Inc., San Jose, CA, USA) as published by Szabo and Gulya (2013) . TI was determined according to Fujita et al. (1996) by using the following formula: [perimeter of cell (lm)] 2 /4p [cell area (lm 2 )]. Color correction and cropping of the light microscopic images were performed when photomicrographs were made for publication and assembled for a panel. Gray-scale digital images of the immunoblots were acquired by scanning the autoradiographic films with a desktop scanner (Epson Perfection V750 PRO; Seiko Epson Corp., Japan). The images were scanned and processed at identical settings to allow comparisons of the Western blots from different samples. The bands were analyzed through the use of ImageJ. The immunoreactive densities of equally loaded lanes were quantified, and all samples were normalized to the internal GAPDH load controls.
All statistical comparisons were made by using R 3.1.0 for Windows (The R Foundation for Statistical Computing; Wirtschafts-Universita¨t, Wien, Austria). Results were analyzed with a two-way ANOVA, and the Bonferroni correction was used to establish significance between groups. Values were presented as mean ± S. D.; p < 0.05 was considered significant; * , ** and *** denote p < 0.05, p < 0.01 and p < 0.001, respectively.
RESULTS

Rosuvastatin affects microglial morphology
The morphological changes elicited by rosuvastatin in unchallenged (control) and LPS-challenged pure microglia cultures were documented through the use of Iba1 immunocytochemistry (Fig. 1A-D) and quantitatively analyzed on binary silhouettes of individual microglial cells ( Fig. 2A-G) . Iba1 protein expression was also monitored during treatments (Fig. 1E) . Most of the unchallenged and untreated (control) microglia displayed ameboid morphology with TI < 3; they had a predominantly ameboid shape, occasionally with small pseudopodia (Figs. 1A and 2A) . When administered alone for 24 h, rosuvastatin induced the formation of numerous microspikes (Figs. 1B and 2B); these slender cytoplasmic projections (filopodia) resulted in significantly increased perimeter and TI values of these cells (Fig. 2F,  G) . Quantitative analysis showed that the average TI in this group increased about 10-fold, to above 19, as compared with the controls (Fig. 2G) . The LPS challenge did not result in any significant morphometric change (Figs. 1C and 2C, E-G). However, rosuvastatin treatment in LPS-challenged cells resulted in a significantly enlarged and more ramified cell form (TI > 7) with a much larger perimeter value as compared with their respective control values (Figs. 1D and 2D , E-G), indicating that rosuvastatin profoundly antagonized the morphological changes characteristic of LPS-induced microglial activation. In relation to the substantially increased size of the LPS-challenged and rosuvastatintreated microglia (Figs. 1D and 2D, E), their Iba1 immunoreactivity was also significantly increased (Figs. 1E and 2E).
Rosuvastatin inhibits proliferation and cell adhesion in both unchallenged and LPS-challenged microglia
Rosuvastatin significantly inhibited cell proliferation in both unchallenged and LPS-challenged cultures, by 47.8% and 68.9%, respectively, after a 24-h treatment period (Fig. 3A) . We used a 16-well E-Plate-based realtime analysis to determine whether rosuvastatin affects cell adhesion. Rosuvastatin inhibited cell adhesion in both unchallenged (control) and LPS-challenged microglia (Fig. 3B ). The differences in levels of inhibition of cell adhesion between cultures with or without rosuvastatin (unchallenged and LPS-challenged microglia vs. rosuvastatin-treated and LPS-challenged + rosuvastatin-treated microglia) were significant by 20 h of culturing and thereafter, probably due to the significantly larger cell populations in the control and LSP-challenged microglial cultures as compared with those in the rosuvastatin or LPS + rosuvastatin-treated cultures (Fig. 3B) , and to the ability of rosuvastatin to stimulate the formation of microspikes (Fig. 2B, D) , i.e. the actin-based filamentous protrusions implicated in the cell motility, and consequently in the decreased adhesion of these cells.
Rosuvastatin reduces phagocytotic activity in LPS-challenged cells
The microglial function is inherently related to its phagocytotic activity. In pure microglial cultures (subDIV4), the control (unchallenged and untreated) microglia exhibited a low level of fluid-phase phagocytosis (Fig. 4A, E) , engulfing only 2.62 ± 1.7 beads per cell (n = 91). Rosuvastatin did not affect the phagocytosis appreciably (Fig. 4B, E) , the number of phagocytosed microbeads remaining low (2.70 ± 1.7; n = 50). As expected, the LPS challenge increased the phagocytotic activity of the microglial cells significantly (Fig. 4C, E) . On average, the LPS-challenged cells accumulated 25.39 ± 11.4 beads per cell (n = 70), and some of the cells engulfed as many as 40 microbeads. In the LPS-challenged microglia, however, rosuvastatin inhibited the phagocytosis drastically, by nearly 80% (Fig. 4D, E) as the fluid-phase phagocytotic activity was returned close to the level of the control cells (4.67 ± 3.9 microbeads per cell; n = 88). As activated microglial cells often damage neuronal tissue, such a strong inhibition of a pro-inflammatory action by rosuvastatin could be beneficial in preventing or ameliorating neurodegeneration.
Rosuvastatin concomitantly decreases pro-inflammatory and increases anti-inflammatory cytokine levels
Activated microglia are known to express several pro-and anti-inflammatory cytokines, while statins are able to reduce the inflammatory effect in the vicinity of atherosclerotic plaques. We therefore expected rosuvastatin to regulate the amount of cytokines released by the microglia. Indeed, when the basal levels of the pro-inflammatory cytokines IL-1b and TNF-a and the anti-inflammatory cytokine IL-10 in unchallenged microglia were compared with the levels from rosuvastatin-treated LPS-challenged or unchallenged cells, a unique regulatory pattern emerged (Fig. 5) . The basal level for IL-1b in unchallenged (control) microglia was 15.00 ± 5.6 pg/ml (Fig. 5A) . Rosuvastatin did not change this level significantly (9.56 ± 13.1 pg/ml). As expected, a 24 h-long LPS challenge significantly elevated the IL-1b level in the activated microglia, to 156.05 ± 63.0 pg/ml. However, when added together with LPS, rosuvastatin significantly inhibited the development of this elevated IL-1b level, by about 45%, to 86.25 ± 49.3 pg/ml. A similarly strong effect of rosuvastatin was demonstrated on the level of TNF-a, another pro-inflammatory cytokine, in LPS-challenged microglial cells (Fig. 5B) . Two different treatment times (6 h and 24 h) were used as the TNF-a production responded quickly to the LPS challenge. The level of TNF-a in the unchallenged (control), rosuvastatintreated microglia could not be detected, but its level quickly rose, to 906.80 ± 281.7 pg/ml in the LPSchallenged cells after 6 h, and the level was still robust after 24 h (188.19 ± 38.6 pg/ml). When rosuvastatin was co-administered to LPS-challenged cells for either 6 h or 24 h, it significantly inhibited the production of TNF-a, by 39% and 40%, respectively (Fig. 5B) .
Moreover, rosuvastatin affected the production of IL-10, an anti-inflammatory cytokine (Fig. 5C) . The basal and rosuvastatin-treated levels of IL-10 in the unchallenged microglia were not significantly different (37.01 ± 18.4 pg/ml vs. 75.32 ± 35.4 pg/ml), although elevated IL-10 production was noted after rosuvastatin treatment. Interestingly, LPS increased the IL-10 protein expression significantly to about 340% of the level of the unchallenged microglia (125.3 ± 25.3 pg/ml pg/ml). When rosuvastatin was co-administered with LPS, it boosted the IL-10 protein expression even higher, to about 750% of the basal level (276.84 ± 85.6 pg/ml), indicating the very strong anti-inflammatory action of rosuvastatin.
Rosuvastatin affects the expression of inflammation-related genes
When the profound morphological and functional effects of rosuvastatin on the pro-and anti-inflammatory capabilities of the microglia had become apparent, we set out to analyze the effects of rosuvastatin on the expression of 122 inflammation-related genes in unchallenged and LPS-challenged pure microglial cells. The hierarchical cluster analysis of 75 such genes is summarized in Fig. 6 , and the genes with 47 of the most noteworthy and significant expression changes in response to treatment are listed in Table 1 . The results of the analysis indicated that treatment with 1 lM rosuvastatin in unchallenged and LPS-challenged microglia could induce either the upregulation or the downregulation of a number of genes. Levels of expression of selected inflammation-related genes (for example, Ccl24, Ccr1, IL-11, Cxcl1, Ccl4, Ccl5, Hspb1, TGFb-2 and Mbl2) are highlighted in Fig. 7 . Some of these genes responded to rosuvastatin in unchallenged or challenged cells, or were affected by the LPS challenge. The genes upregulated by the LPS challenge included those coding for chemokine ligands 1, 2, 4, 5, 9, 19 and 24 (Cxcl1 = 111.6-fold, Ccl2 = 34.5-fold, Ccl4 = 17.6-fold, Ccl5 = 147.0-fold, Cxcl9 = 118.2-fold, Ccl19 = 5.2-fold and Ccl24 = 24.6-fold), IL-11 . Only a few genes were downregulated by the LPS challenge, the most affected one being that of the myosin regulatory light chain 2 (Myl2 = À4.4-fold).
Rosuvastatin treatment in unchallenged cells affected fewer, but similarly important microglial genes involved in pro-and anti-inflammatory processes. The genes upregulated by rosuvastatin included Cxcl1 (7.0-fold; Fig. 7D ), the anti-inflammatory Ccl5 (6.6-fold; Fig. 7F) , and, most importantly, Mbl2 (126.2-fold; Fig. 7I ), a crucial factor in the development of innate immunity (Worthley et al., 2005) . Rosuvastatin was in general a weak inhibitor of the expression of inflammatory genes as it downregulated only a few genes, notably the antiinflammatory interleukin-10 (Il10 = À4.0-fold) and the pro-inflammatory chemokine (C-C motif) receptor 1 (Ccr1 = À2.9-fold). When rosuvastatin was applied to LPS-challenged cultures (Table 1, Figs. 6 and 7), a more complex picture emerged. Some of the LPS-upregulated genes were inhibited by rosuvastatin, as seen in the case of Ccl24, where a substantial, 377% decrease in gene expression was observed, down from the 24.5-fold increase after LPS treatment to a 6.5-fold increase (Fig. 7A) , or in the case of Ccr1, where a 198% decrease in gene expression was detected (Fig. 7B) . Interestingly, rosuvastatin alone did not exhibit a strong effect on these latter genes, but only when activated by LPS (Fig. 7C, D) . Other genes were regulated synergistically by rosuvastatin when applied to LPS-challenged microglia. For example, Cxcl1 and Ccl4 were both further upregulated by rosuvastatin in LPS-challenged cells (Fig. 7D, E) . Some of the genes related to inflammation were not affected by the LPS challenge, but reacted weakly to rosuvastatin, as seen in Hspb1 gene expression (Fig. 7G, H) , where a 2.8-fold increase was detected.
DISCUSSION
We carried out a quantitative investigation of the complex morphological, functional and gene expression characteristics of pure microglial cells of embryonic origin after rosuvastatin treatment in unstimulated and LPS-challenged cultures, and highlighted the complex beneficial effects of rosuvastatin that make it an excellent candidate for preventive neuroinflammatory therapy with well-balanced properties of enhanced antiinflammatory and subdued pro-inflammatory effects. Although microglial cells prepared from embryonic nervous tissue may differ from those of the adult brain in certain characteristics (Floden and Combs, 2006) , they are nevertheless similarly responsive to immunological (LPS) challenge and suitable for morphological, functional and gene expression studies. When activated, the microglia display both pro-and anti-inflammatory properties as they can be polarized along a continuum toward a detrimental (M1) or a beneficial (M2) state in the injured CNS (Kroner et al., 2014) . Inflammation that is mediated, and perhaps enhanced, by the microglia has been implicated in a number of neuropathological conditions, ranging from acute injuries (Loane and Byrnes, 2010) and chronic inflammatory conditions (Gay, 2007; Napoli and Neumann, 2010) to neurodegenerative diseases (LongSmith et al., 2009; Prokop et al., 2013) .
Statins are commonly used in the treatment of high blood cholesterol levels (Burg and Espenshade, 2011) . They are classified on the basis of their lipid-lowering efficacy and their lipophilic/hydrophilic nature (Hamelin and Turgeon, 1998; Jones et al., 1998; Davidson, 2002; Schachter, 2005) ; while lipophilic statins penetrate the cell membrane, hydrophilic statins such as rosuvastatin (Crestor; AstraZeneca Pharmaceuticals, LP, Wilmington, DE, USA) are transported through the blood-brain barrier via multiple transporters (Kitamura et al., 2008; Abbott et al., 2010; Ellis et al., 2013) or ATP-binding cassette efflux transporters in microglia (Gibson et al., 2012) . Rosuvastatin exhibits the greatest inhibitory effect on cholesterol biosynthesis (McTaggart et al., 2001 ) and most favorably alters the high-density lipoprotein profile among statins (Asztalos et al., 2007) ; it was the fourth highest-selling prescription drug in the USA in 2013 (http://www.drugs.com/stats/top100/2013/sales). 5 . Rosuvastatin reduces the pro-inflammatory cytokine IL-1b and TNF-a levels and increases the anti-inflammatory IL-10 production. Pure microglial cultures (subDIV4) were maintained and treated as described in Experimental procedures section. After treatments for 6 or 24 h, immunoreactive protein levels (pg/ml ± S.D.) for IL-1b (A), TNF-a (B) and IL-10 (C) were detected by ELISA. TNF-a production was measured after 6 h and 24 h (B). As expected, pro-inflammatory cytokine production was significantly increased in the LPS-challenged cells (A, B) . Rosuvastatin was a potent inhibitor of this effect for both IL-1b (A) and TNF-a (B). The level of the anti-inflammatory cytokine IL-10 was measured after 24 h (C). Rosuvastatin slightly increased the level of IL-10 both in unchallenged and in LPS-challenged microglia, to 750% of the control level in the latter case (C). Error bars indicate mean ± S.D. of six replicate measurements from three independent culturings. Data were analyzed with a two-way ANOVA. n.d. = not detected. Although their main action is to block cholesterol synthesis, other effects of statins, including those on the regression of atherosclerotic coronary lesions, are also important (Wierzbicki et al., 2003) . Expecting similarly beneficial effects on the microglia, we determined how rosuvastatin modulates both pro-and anti-inflammatory actions by affecting numerous morphological, functional and gene expression parameters in pure microglial cultures. These cultures provide a unique opportunity to study these functional and expression parameters without the significant influence of any contaminating cell types. Our secondary microglial cultures were >99% pure, a crucial factor when levels of secreted pro-and antiinflammatory peptides or gene expression levels are measured, as other cell types in the CNS are also capable of expressing such peptides (Gruol et al., 2014) .
Our studies revealed the effects of rosuvastatin on various quantitative morphological properties of the microglia. Rosuvastatin affected the area, perimeter and TI profoundly in both unchallenged and LPS-challenged cells. It generally promoted microspike formation and increased the cell perimeter and TI through ramification. Concomitantly with the increase in cell area in both unchallenged and LPS-challenged cells, rosuvastatin affected the protein synthesis of Iba1, a protein that is implicated in actin cytoskeleton remodeling (Sasaki et al., 2001; Ohsawa et al., 2004) . As expected, LPS treatment caused microglia activation that resulted in a low TI, but the combined treatment with LPS + rosuvastatin inhibited this activation through the development of microspikes and the cells becoming more ramified.
Rosuvastatin strongly inhibited microglia proliferation and adhesion as it significantly decreased the number of cells in both naı¨ve and LPS-challenged cultures. Although the precise mechanisms are not known, statins are able to inhibit mitosis through cell cycle arrest in G1 (Yang et al., 2008) and G2/M . As rosuvastatin displays a weak anti-mitogenic effect, its regular use may prove helpful in lowering the risks of a number of cancer types (Simon et al., 2012) . To quantify cell adhesion, we used the cell index value (Atienza et al., 2005; Jarvis et al., 2011) . Our finding that rosuvastatin lowered cell adhesion in both unchallenged and LPS-challenged cells is in harmony with previous reports on the ability of statins to decrease the expression of cell adhesion molecules (Weber et al., 1997; Wierzbicki et al., 2003) .
We also examined how rosuvastatin altered fluidphase phagocytosis. Phagocytosis is crucial in both the normal and the pathologic CNS as it efficiently eliminates foreign materials, apoptotic cells and cell debris (Kettenmann et al., 2011) , and alteration of this clearance function could be harmful (Hickman and El Khoury, 2014; Lue et al., 2015) . For example, proinflammatory phenotypes are linked to the phagocytic activity, and the blocking of phagocytosis may prevent some forms of inflammatory neurodegeneration, and might therefore be beneficial during infection, trauma, ischemia, neurodegeneration and aging (Neher et al., 2011; He et al., 2014) . LPS is a strong activator of microglial phagocytosis (Nakamura, 2002; Lund et al., 2006; Szabo and Gulya, 2013) . In our study, rosuvastatin inhibited phagocytosis completely in the LPS-challenged microglia, while it was ineffective in inhibiting the basallevel phagocytosis in unchallenged cells, indicating that rosuvastatin is a potent inhibitor of this function only in pro-inflammatory situations and does not alter the normal clearance of cell debris in a healthy tissue. Thus, rosuvastatin could be helpful when excess microglial activity could harm the nervous tissue. Cytokines, important immunomodulators in the normal functioning of the CNS, can be released, among others, by the microglial cells. Cytokines can also be harmful: previous studies have shown that neurodegeneration originating through neuroinflammation is often elicited by activated microglia McGeer, 2003, 2010) through the release of different pro-inflammatory cytokines and chemokines (Hanisch, 2002) . High levels of IL-1b could be observed, for instance, in the vicinity of amyloid plaques of AD patients (McGeer et al., 1993; Lindberg et al., 2005; Ghosh et al., 2013) , where activated microglia accumulate (Rodriguez et al., 2014) . Previous studies also suggested that statins reduce levels of some of the pro-inflammatory cytokines (Lindberg et al., 2005; Nakamichi et al., 2006; Veillard et al., 2006) and increase the anti-inflammatory cytokine IL-10 ( Scho¨nbeck and Libby, 2004) . As expected, both pro-(IL-1b, TNF-a) and anti-inflammatory cytokines (IL-10) were increased in LPS-challenged cells as compared with the unchallenged (control) group. Rosuvastatin did not significantly affect the basal cytokine levels in unchallenged microglia, but strongly inhibited levels of the pro-inflammatory cytokines IL-1b and TNF-a when tested in LPS-challenged cells. Besides the inhibition of these pro-inflammatory agents, rosuvastatin exerted a direct anti-inflammatory effect by elevating the level of IL-10 in both unchallenged and LPS-challenged cells.
Effects of rosuvastatin on such diverse immune mechanisms of microglia as phagocytosis and cytokine production indicated a strong likelihood of its involvement in many other immune system-wide functions and possible effects on inflammation-related genes. We demonstrated that rosuvastatin, LPS and their combination had differential effects on the expression of inflammation-related genes. Several genes were upregulated after LPS challenge, confirming (Shimoyama et al., 2015) at http://rgd.mcw.edu/. Data are expressed as fold-change over the expression of unchallenged and untreated (control) microglial cells. Treatments had different effects on inflammation-related genes. LPS mostly induced the upregulation of genes as compared with the untreated control microglia. Rosuvastatin alone also had some effects on these genes. Combined treatment demonstrated that rosuvastatin had different effects on LPS-activated microglia cells: inhibited the effect of LPS on certain genes (e.g. Ccl24, Ccr1, Kng1, Nos2, Il11), while it had a synergistic effect with LPS on others (e.g. Cxcl1, Ccl4, Il23r).
its strong pro-inflammatory effects on the microglia. Rosuvastatin itself and in combination with LPS displayed different effects on gene expression. Although rosuvastatin was not able to decrease all the LPSupregulated genes, it suppressed the pro-inflammatory effects of LPS on some genes such as Ccl24 or Ccr1. Ccl24 is a chemokine that can readily be upregulated by pro-inflammatory cytokines or microbial stimulus such as LPS (Watanabe et al., 2002) . Ccr1 is implicated in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Previous studies suggested that Ccr1 could be upregulated in EAE (Rottman et al., 2000) , and the microglia expressed Ccr1 around the demyelinating plaques, making Ccr1 antagonists or inhibitors possible targets for the development of MS-therapy (Hesselgesser et al., 1998; Eltayeb et al., 2007) . Rosuvastatin additionally increased the expression of certain genes. Its general effects on microglia were predominantly anti-inflammatory. The gene most upregulated by rosuvastatin was Mbl2, which is important in innate immunity (Worthley et al., 2005; Ip et al., 2009) and involved in the stimulation of phagocytosis (Stuart Fig. 7 . Relative expression levels of various inflammation-related genes identified by real-time PCR in pure microglia cells. Pure microglial cultures (subDIV4) were maintained and treated as described in Experimental procedures section. The cells (subDIV4) were cultured with or without LPS for 24 h in the presence or absence of rosuvastatin. The extraction of total RNA and the real-time PCR are described in Experimental procedures section. The transcription levels of the chemokine ligand 24 (Ccl24, A), the chemokine receptor 1 (Ccr1, B), IL-11 (C), the chemokine (CXC motif) ligand 1 (or melanoma growth-stimulating activity, alpha), (Cxcl1, D), the chemokine ligand 4 (Ccl4, E), the chemokine ligand 5 (Ccl5, F), the heat shock protein 1 (Hspb1, G), the transforming growth factor beta (TGFbl-2, H) and the mannose-binding lectin (protein C) 2 (Mbl2, I) are shown in unstimulated (control), LPS-challenged and LPS-challenged + rosuvastatin-treated cells. For some pro-inflammatory genes, rosuvastatin inhibited their expression which was upregulated in LPS-challenged cells. In connection with Cxcl1, Ccl4 and Ccl5, the combined treatment revealed synergistic effects between rosuvastatin and LPS for Cxcl1, Ccl4 and Ccl5. Rosuvastatin increased levels of expression of Hspb1, TGF-b and Mbl2. Relative expression levels (on a log 2 scale) ± SD from at least four separate experiments are shown for each condition. Data were analyzed with a two-way ANOVA. , 2005) . Hspb1 was also upregulated by rosuvastatin. Hspb1 is a heat-shock protein with strong anti-apoptotic potential that regulates the cytoskeleton dynamics through F-actin stabilization (Concannon et al., 2003) . Cxcl1 has been reported to be an antiinflammatory protein with a neuroprotective role (Omari et al., 2009) . Additional chemokine genes such as Ccl2 (El Khoury et al., 2007; El Khoury and Luster, 2008) , Cxcl1 (Bosivert et al., 2006) and Ccl5 were all upregulated in our studies and implicated in microglia recruitment to areas of inflammation. Although Ccl5 has been demonstrated to induce pro-inflammatory mechanisms (Skuljec et al., 2011) , it has also been shown to ameliorate AD-like pathology by recruiting microglia to b-amyloid deposits (Lee et al., 2012) . The expression of a number of phagocytosis-related gene was also tested. For example, Mbl2 was upregulated in rosuvastatin-treated microglia in a seemingly contradictory action, while several other genes known to be involved in phagocytosis were inhibited, as expected from the phagocytosis essays, by rosuvastatin (for example Myl2 (À1.27), Sirpa (À1.50), Elmo1 (À1.05), or CD47 (À1.07)). Although the overall downstream effect in the microglia is a strong inhibition of phagocytosis upon rosuvastatin treatment, it remains to be seen as to what intracellular signalization is activated to affect these genes or how these genes interact to elicit this particular cell response.
In summary, rosuvastatin elicits robust changes in the microglial functions in vitro as it potently inhibits the harmful pro-inflammatory signals and significantly enhances the beneficial anti-inflammatory actions of pure microglial cells after LPS challenge. Its effects include anti-mitogenic and anti-phagocytic action, strong inhibition of the synthesis of pro-inflammatory cytokines paralleled by a very strong stimulation of antiinflammatory cytokine production, and a beneficial differential expression of a number of inflammationrelated genes. As activated microglia often damage neuronal tissues by excessive cytokine and chemokine production and phagocytosis, the strong inhibition of such pro-inflammatory action by rosuvastatin illustrates an advantageous effect of this drug. Thus, rosuvastatin may be used prophylactically to inhibit pro-inflammatory and activate anti-inflammatory mechanisms of the microglia in order to reduce neuroinflammation and consequently neurodegeneration substantially. The microglia could therefore be a novel, specific therapeutic target in the fight against neurodegenerative disorders.
